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Background: Three decades of research suggests that prevention of iron deficiency anemia (IDA) in the primary
care setting may be an unrealized and unique opportunity to prevent poor developmental outcomes in children. A
longitudinal study of infants with IDA showed that the developmental disadvantage persists long term despite iron
therapy. Early stages of iron deficiency, termed non-anemic iron deficiency (NAID), provide an opportunity for early
detection and treatment before progression to IDA. There is little research regarding NAID, which may be associated
with delayed development in young children. The aim of this study is to compare the effectiveness of four months
of oral iron treatment plus dietary advice, with placebo plus dietary advice, in improving developmental outcomes
in children with NAID and to conduct an internal pilot study.
Methods/Design: From a screening cohort, those identified with NAID (hemoglobin ≥110 g/L and serum
ferritin <14 μg/L) are invited to participate in a pragmatic, multi-site, placebo controlled, blinded, parallel group,
superiority randomized trial. Participating physicians are part of a primary healthcare research network called
TARGet Kids! Children between 12 and 40 months of age and identified with NAID are randomized to receive
four months of oral iron treatment at 6 mg/kg/day plus dietary advice, or placebo plus dietary advice (75 per
group). The primary outcome, child developmental score, is assessed using the Mullen Scales of Early Learning
at baseline and at four months after randomization. Secondary outcomes include an age appropriate behavior
measure (Children’s Behavior Questionnaire) and two laboratory measures (hemoglobin and serum ferritin levels).
Change in developmental and laboratory measures from baseline to the end of the four-month follow-up period will
be analyzed using linear regression (analysis of covariance method).
Discussion: This trial will provide evidence regarding the association between child development and NAID, and the
effectiveness of oral iron to improve developmental outcomes in children with NAID. The sample size of the trial will
be recalculated using estimates taken from an internal pilot study.
Trial registration: This trial was registered with Clinicaltrials.gov (identifier: NCT01481766) on 22 November 2011.
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Prevalence of iron deficiency and iron deficiency anemia
Nationally representative data from the United States in-
dicates a prevalence in children one to three years of age
of 9% and 3%, for iron deficiency and iron deficiency
anemia (IDA), respectively [1,2]. European children (one
to three years of age) have been reported to have similar
rates: 5 to 20% for iron deficiency and 3 to 9% for IDA
[3]. Although there are no similar nationally representa-
tive data for Canadian children, regional studies suggest
a similar rate that has led Hartfield to conclude that
‘iron deficiency is an inadequately addressed and signifi-
cant public health problem among Canadian infants and
children’ [1,2,4-13].
Current recommendations regarding screening for iron
deficiency anemia in primary care practice
The American Academy of Pediatrics (AAP) has con-
cluded that universal screening for anemia should be
performed, with determination of hemoglobin concen-
tration, at approximately one year of age [14]. Universal
screening should also include an assessment of risk fac-
tors associated with iron deficiency: prematurity, low
birth weight, exposure to lead, exclusive breastfeeding
beyond four months of age without supplemental iron,
weaning to whole milk or complementary foods that do
not include iron-fortified cereals or foods naturally rich
in iron, feeding problems, poor growth, and low socioeco-
nomic status. Selective screening should be performed at
any age when these risk factors for iron deficiency and IDA
have been identified [13]. However, both the Canadian
Task Force on the Periodic Health Examination (1994) and
the United States Preventive Services Task Force (2006)
have concluded that the evidence is insufficient to rec-
ommend for or against routine screening for IDA in
asymptomatic children [15,16]. These guidelines have
focused on IDA, but have not addressed screening for
non-anemic iron deficiency (NAID). Furthermore, experts
have highlighted the lack of evidence and paucity of high
quality investigations on which to base guidelines relevant
to iron deficiency [17].
Current evidence on early child development and iron
deficiency anemia
Studies of the outcomes of IDA have been largely con-
ducted in developing countries due to its high prevalence.
Poor developmental outcomes of IDA, which persist long
term despite iron therapy, have been summarized in two
recent reviews of longitudinal observational studies
[14,18]. A Cochrane systematic review that was updated in
2013 examined the effectiveness of longer term iron treat-
ment, and demonstrated improvements in developmental
outcomes for the IDA group receiving oral iron treatment,
compared to those receiving placebo [19,20]. Studiesincluded in the review also demonstrated that it is possible
to detect meaningful changes in tests of children’s cogni-
tion over a four-month-period. Although the authors of
the Cochrane review concluded that there is an urgent
need for further randomized trials in children with IDA
with long term follow-up periods, there have been no
recent trials; most investigators currently consider the
question of the association between IDA and development
to lack equipoise.
Current evidence on early child development and non-
anemic iron deficiency
The authors of the current protocol (KA and PCP) have
recently undertaken a systematic review of the literature
regarding the effectiveness of oral iron treatment to im-
prove the developmental and hematologic outcomes of
young children with NAID [21]. From the titles of 743
articles, a full-text review was completed on 46, and two
randomized controlled trials were found for preschool-
aged children with NAID treated with oral iron, 3 to 6
mg/elemental iron/kg daily, versus no treatment [22,23].
For both studies, the primary objective was to study chil-
dren with IDA; however, both included children with
NAID randomized to oral iron or no treatment, and this
data was available. The first study (n = 29, conducted in
Indonesia, published in 1993) showed no statistically sig-
nificant difference between groups in the post-treatment
developmental score [23]. The second study (n = 40,
conducted in Turkey, published in 2004) showed a sta-
tistically significant difference between groups in the
post-treatment mental developmental score, but not in
the psychomotor developmental score [22]. Meta-analysis
was not possible due to significant heterogeneity. Both
studies showed moderate risk of bias due to insufficient
information regarding allocation concealment and inad-
equate reporting of adjustment for covariates (notably,
sociodemographic variables); furthermore, mothers were
not blinded in the second trial as a placebo was not used.
We have concluded that the effectiveness of oral iron
treatment in children with NAID to improve developmen-
tal outcomes remains in question, and with this equipoise
it is ethical and urgent to conduct such a trial. The results
of a high quality, adequately powered trial, conducted in a
developed country, will begin to establish an evidence base
for screening for iron deficiency, with an aim to improve
developmental outcomes.
Establishment of the TARGet kids! research network
The investigators of this protocol (PCP, CSB, and JLM)
have established a program of research aimed at advancing
the scientific basis for preventative primary healthcare for
young children. This includes development of a primary
care practice-based research network called TARGet Kids!
to conduct observational and interventional studies in
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primary prevention [24]. It represents an innovative collab-
oration between child health researchers in the Faculty of
Medicine at the University of Toronto, and children’s pri-
mary care physicians (pediatricians and family physicians)
from the Department of Pediatrics and the Department of
Family and Community Medicine, also at the University of
Toronto.
Between June 2008 and September 2013, more than
5,000 children, under six years of age have been enrolled
in the TARGet Kids! Cohort, with a collection of non-
invasive measures, including questionnaires, and phys-
ical measures, and laboratory testing has been completed
in more than 2,500 children [24]. We have leveraged
existing TARGet Kids! infrastructure, collaborations, re-
search personnel, and data management system to carry
out this randomized controlled trial.Developing a focus in child development
Since September 2008, TARGet Kids! data collection in-
cludes the measurement of child behavior (temperament)
through a parent-completed questionnaire (Children’s
Behavior Questionnaire). We have found that children
aged between three and five years, with high ‘negative
affect’, are at higher nutrition risk [25]. In the current
trial, we aim to expand our focus in child development.
In order to reach this goal we have established collabora-
tions with researchers in child development. Including a
focus in child development in the overall TARGet Kids!
initiative is a strategic opportunity, given the importance
of healthy developmental trajectories as a critical outcome
measure for children [26,27].
Rationale for a focus of research to optimize early child
development through screening for non-anemic iron
deficiency in the primary care practice setting
Iron status can be considered as a continuum from nor-
mal iron status, to iron deficiency without anemia, and
finally, IDA [28]. NAID is the early latent stage of iron de-
ficiency. In NAID, the amount of stored iron is reduced,
but the amount of functional iron may not be affected;
thereby children who have NAID have no iron stores to
mobilize if the body requires more iron [28]. If iron is not
provided, NAID may progress to IDA, the most severe
form of iron deficiency. This natural history provides an
opportunity for early detection through screening by
physicians in primary care settings.
Early detection of NAID presents an important oppor-
tunity to provide effective interventions which may improve
child developmental outcomes. There are critical gaps in
knowledge regarding the effectiveness of iron interventions
in improving the development of young children with
NAID. This proposal can address this gap, and also assessthe feasibility of screening for NAID in the primary care
setting.
Trial objectives and hypotheses
The primary objective of this trial is to assess the effective-
ness of four months of oral iron plus dietary advice versus
placebo plus dietary advice, in children with NAID aged 12
to 40 months, to improve their developmental outcomes.
We hypothesize that children receiving four months of oral
iron plus dietary advice will have better developmental out-
comes than those who receive placebo plus dietary advice.
Secondary objectives include comparing four months of
oral iron treatment plus dietary advice versus placebo plus
dietary advice, for the following secondary outcomes:
laboratory measures of iron indicators (serum ferritin
and hemoglobin), and behavioral outcomes such as
temperament, in children with NAID.
Methods/Design
Study design
The ‘Optimizing Early Child Development for Young
Children with Non-Anemic Iron Deficiency in the Primary
Care Practice Setting’ (OptEC) study is designed as a
multi-site, pragmatic, placebo controlled, superiority ran-
domized trial. From a screened cohort, children identified
with NAID are randomly allocated in a 1:1 ratio to each
treatment group. This trial has been designed along the
pragmatic end of the pragmatic-explanatory continuum,
since it was designed to primarily inform decision making
[29]. Specifically, eligibility criteria, participant compliance,
intensity of follow-up, and primary analysis follow
pragmatic approaches, while practitioner expertise and
adherence, intervention, and follow-up of outcomes follow
approaches midway along the pragmatic-explanatory
continuum. This protocol was designed following the
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) guidelines (see Additional file 1),
and results will be reported according to the 2008 Con-
solidated Standards for Reporting Trials (CONSORT)
guidelines for pragmatic trials [30,31].
Setting
This multi-site study is being conducted in the offices of
primary care practices participating in the TARGet Kids!
practice-based research network. The Optimizing Early
Child Development in the Primary Care Practice Setting:
Pragmatic Randomized Trial of Iron Treatment for Young
Children with Non-anemic Iron Deficiency (OptEC) trial
is embedded in the TARGet Kids! cohort. The screening
cohort includes all eligible children attending their
well-child visit with their primary care physician. To date,
TARGet Kids! practice sites are located in Toronto,
Ontario. There are currently seven pediatric practices
and three family medicine practices involved in patient
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practicing physicians.
Participants
Children aged 12 to 40 months, whose parents consent
to participate in the TARGet Kids! study, constitute the
screening cohort of this trial. These parents are given a
letter containing a short description of the OptEC trial.
This letter states that if their child is found eligible, the
parents will be contacted by phone to invite them to
participate in the OptEC trial.
Eligibility for randomization
All participants in the screening cohort undergo laboratory
screening for iron deficiency, and children are assigned to
one of three categories based upon the results of their
hemoglobin, serum ferritin, and C-reactive protein (CRP):
1. NAID, determined by hemoglobin ≥110 g/L, serum
ferritin <14 μg/L, and CRP <10 mg/L.
2. IDA, determined by hemoglobin <110 g/L, serum
ferritin <14 μg/L, and CRP <10 mg/L.
3. IS, determined by hemoglobin ≥110 g/L, serum
ferritin ≥14 μg/L, and CRP <10 mg/L.
In this trial, only children diagnosed with NAID are ran-
domized to the intervention and control groups. The
other two groups (IDA and IS) are non-randomized com-
parators (Figure 1: schematic of study plan). However, for
all three groups, we exclude children with any of the
following: a CRP level ≥10 mg/L; a previously diagnosedFigure 1 Study schematic of the ‘Optimizing Early Child Developmen
Randomized Trial of Iron Treatment for Young Children with Non-Ane
Questionnaire/Early Childhood Behavior Questionnaire/Children’s Behaviordevelopmental disorder; a genetic, chromosomal or
syndromic condition; chronic medical condition (with the
exception of asthma and allergies), including chronic
anemia, iron deficiency, or recent oral iron supplementa-
tion or treatment; prematurity, with a gestational age of
less than 35 weeks; low birth weight less than 2,500 g;
attending the office for an acute illness, such as a viral
illness, or other health concern other than for a well-child
assessment; any contraindications to receiving elemental
iron; the use of any natural health product containing the
same medicinal ingredient(s) as the investigational
product; or if English is not spoken to the child in the
home or in a child care setting.
Intervention and control
Children with NAID are randomized to receive either oral
iron treatment (6 mg elemental iron/kg/day) or placebo
(equivalent volume) in two divided doses for four months
[32]. A drop-based formulation containing ferrous sulfate
(Fer-In-Sol™, Mead Johnson Nutrition, Evansville, Indiana,
USA) was chosen as the active agent to facilitate ease of
administration to young children. The placebo is devel-
oped by the Hospital for Sick Children compounding
pharmacy, and similar in color and taste to the active
agent.
Children in both the oral iron and placebo group are
also given dietary advice to improve iron intake. A
guideline for improving iron intake was developed to
serve this purpose (see Additional file 2: iron intake
guideline). It is based on the recommendations in Canada’s
Food Guide and the Hospital for Sick Children’s onlinet in the Primary Care Physician Practice Setting: Pragmatic
mic Iron Deficiency’ (OptEC) trial. IBQ/ECBQ/CBQ: Infant Behavior
Questionnaire.
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Dietary advice includes recommendations on the var-
ied sources of foods containing high amounts of iron,
foods that increase and inhibit iron absorption, and
dietary habits that may prevent iron deficiency (such
as maximum daily cow’s milk intake and limiting the
intake of juice).
Concomitant interventions permitted include over the
counter multivitamins which do not contain iron; those
prohibited include additional over the counter iron and
prescription iron. To monitor adherence at the end of
the trial, parents are asked to return bottles, and the
amount of iron administered is calculated based on the
volume of solution remaining. Parents in both groups
are advised of possible adverse effects of oral iron (con-
stipation and black stools), which are reversible and
non-harmful, and are encouraged to remain compliant if
these develop. A participant information sheet that con-
tains information on the study drug is provided to parents
who agree to participate in the trial. No specific criteria
are being used for discontinuation or modification of the
interventions, as the dose of iron is within the safe and
recommended dosages for children [32].
Assignment of the interventions to the treatment groups
is randomized and the randomization is stratified by clinic
site. Block randomization is generated with blocks of vari-
able sizes to ensure that group sizes are similar at the end
of each block [35]. The randomization sequence for each
clinic site is generated using computer-generated random
numbers by KT (biostatistician). Allocation concealment
is achieved by having the pharmacy department at the
Hospital for Sick Children prepare the treatment and pla-
cebo in sealed, serially numbered bottles of similar appear-
ance and weight, according to the allocation sequence.
Parents, attending physicians, laboratory personnel, and
study personnel conducting the outcome assessments, and
data analysts and investigators are blind to the group
allocation. Study medication and placebo are supplied in
bottles that look identical, and the appearance, consistency,
and taste of the liquid are similar. Group allocation will
remain concealed until the final data analysis is performed.
If a subject in the randomized study deteriorates or has
persistent, severe, bothersome side effects then unblinding
may be necessary. Emergency unblinding will only be
done when the clinical treatment of the patient will be
different by knowing which arm of the study the patient
was on. The physician caring for the subject will contact
the principal investigator or co-investigator first to discuss
the unblinding procedure. The study investigators should
remain blinded if possible.
Non-randomized children
Children who are identified with IDA and IS constitute
the non-randomized part of the OptEC trial (Figure 1:schematic of study plan). Children with IDA receive oral
iron treatment, 6 mg elemental iron/kg/day, in two di-
vided doses for four months plus dietary advice, which is
considered standard of care. Children with IS do not re-
ceive any intervention.
Outcomes and measures
The primary outcome for the OptEC trial is the Early
Learning Composite (ELC), assessed using the Mullen
Scales of Early Learning (MSEL). The MSEL measures five
distinct developmental skills: gross motor and four ‘cogni-
tive’ skills (fine motor, visual reception, receptive language,
and expressive language). The four cognitive skills are
summarized and converted into age-adjusted normalized
ELC scores, which has a mean of 100 and a standard
deviation of 15 [36]. Secondary outcomes include two
laboratory measures of iron status (hemoglobin and
serum ferritin levels) and measurement of individual
child behavior characteristics (known as child tempera-
ment), which is assessed using age-appropriate parent
reported questionnaires: the Infant Behavior Question-
naire (IBQ), the Early Childhood Behavior Question-
naire (ECBQ), or the Children’s Behavior Questionnaire
(CBQ).
Rationale for selection of outcome measures for this
study
Assessment of cognitive and motor function
The MSEL is an individually administered scale for assess-
ment of development that may be applied to young chil-
dren from birth to 68 months [36]. The standardization
sample mainly represented Caucasian American children
from urban communities with middle class socioeconomic
status. All scales of this tool have adequate test floors: that
is, a child of any age can score at least two standard devia-
tions below their respective means. Administration of the
MSEL requires approximately 30 to 40 minutes. The psy-
chometric properties of the MSEL have been shown to be
adequate [37].
The MSEL has been used to assess development in sev-
eral pediatric conditions, including autism spectrum disor-
ders, profound hearing loss, genetic conditions, biliary
atresia, language delay, and congenital hypothyroidism
[38-41]. Although the Bayley Scales of Infant Development
(BSID) is the most common development assessment tool
used in previous studies of iron deficiency, a recent study
has demonstrated that the BSID may underestimate de-
velopmental delay in children [19,42]. For the current
study, considering its strong psychometric properties,
similarity of the population used in this trial with the
standardization population, and its extensive use in the
pediatric population, the MSEL has been selected as
the scale to assess cognition and motor development in
children.
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There is a reported association between iron deficiency
and altered infant social-emotional behavior, including
shyness, frustration, poor engagement, soothability, and
affect, as measured in laboratory settings [43-45]. We
have selected three age-appropriate validated parent-
completed questionnaires for the assessment of individ-
ual characteristics of child behavior, specifically known
as child temperament: the IBQ for infants aged 12 to 17
months old, the ECBQ for toddlers aged 18 to 36
months), and the CBQ for preschoolers aged 37 to 72
months [46,47]. Three dimensions of temperament are
measured: negative affectivity, surgency or extraversion,
and effortful control. Our research team has recently
studied pre-school children’s temperament using the
CBQ and found children who scored highly on the nega-
tive affectivity scale had significant association with
higher nutrition risk, suggesting that child temperament
may be associated with nutritional disorders such as
obesity and iron deficiency [25].
Laboratory measures of iron status (hemoglobin and serum
ferritin)
The hemoglobin cut-off level of >110 g/L distinguishes
anemia from non-anemia in children under five years of
age [1,2,18]. In adults, serum ferritin has been found to
be the most appropriate test for diagnosis of IDA, with a
cut-off level of ≤15 μg/L, and a recommended cut-off
level of <10 or <12 μg/L for children [14,48,49]. Our
laboratory measures serum ferritin using a Roche
modular platform (Roche Diagnostics Limited, Rotkreuz,
Switzerland) and hemoglobin is measured using the Sys-
mex platform (Sysmex Canada, Mississuaga, ON, Canada)
[50,51]. The Roche modular platform uses a corrective
method to analyze serum ferritin [52]. This correction
increases the cut-off level of serum ferritin for children
to <14 μg/L. Hence, for operational purposes, our trial
uses this corrective value of <14 μg/L of serum ferritin
to distinguish between iron deficiency and iron suffi-
ciency. Other population-based research, such as the
National Health and Nutrition Examination Survey
(NHANES), uses similar serum ferritin levels to identify
iron deficiency in children [52].
Because serum ferritin is an acute phase reactant, con-
current measurement of CRP has been recommended
[14]. An elevated level of CRP suggests that the ferritin
level may be falsely elevated [53]. Hence, we excluded
these children from our sample.
Participant timeline
Participants (NAID, IDA, and IS) are assessed at three time
points: baseline, four, and 12 months after the baseline
visit. At the baseline assessment children are first screened
for serum ferritin, hemoglobin, and CRP to identify theiriron status. A venous blood sample (3 mL) is used to meas-
ure the baseline iron status. According to the results of the
screening laboratory test, those who are eligible and agree
to participate in the OptEC trial are asked to come back to
the physician’s office to complete their baseline develop-
mental testing (MSEL). Other baseline data include a
parent-completed, standardized data collection form based
on questions used in the Canadian Community Health
Survey [54]. The following data is collected: child and
family characteristics (including demographic data, so-
cioeconomic status, ethnicity, family structure, child
care, and familial illnesses), child diet, physical activity,
and health. Individual child behavior characteristics
known as child temperament are also assessed using
the IBQ, ECBQ, or CBQ. Measurement of height and
length, weight, and waist circumference of participants
and their accompanying parent is performed using
standardized anthropometric protocols [55].
After the baseline assessment, intervention is provided
for four months. The four-month follow-up visit is con-
sidered the time of the primary outcome assessment,
and includes measurement of: development (MSEL),
temperament (IBQ, ECBQ, or CBQ), and anthropomet-
ric and laboratory tests (serum ferritin, hemoglobin, and
CRP). Parents are asked to complete a follow-up ques-
tionnaire (Additional file 3: four-month follow-up form)
that collects data related to administration of the study
drug, causes of non-adherence, adverse effects, and an
approximate per week rate of missed doses of the study
drug. The questionnaire also collects data on children’s
frequency of illness during the 4 month period.
The 12-month follow-up visit is a non-intervention
longitudinal follow-up visit for children in all three iron
groups (Table 1: Schedule of procedures, assessments,
and interventions). At the 12-month follow-up visit devel-
opmental, temperament, anthropometric, and laboratory
(serum ferritin, hemoglobin, and CRP) testing is performed.
Recruitment and retention
The TARGet Kids! consent form informs parents that
their child, once enrolled in the cohort, may be eligible
for a trial (such as the OptEC trial). Based on the labora-
tory results of the screening cohort, research assistants
(RA) are instructed to contact the parents of potential
participants by phone and request that they return to
the physician’s office if they agree to participate. The
RAs are provided with a scripted telephone dialogue in
order to standardize the patient recruitment process. At
the physician’s office, the RA reviews the consent form
with the parent, and the clinic nurse reviews the iron
status of the child with the parent and obtains informed
written consent. The family has the opportunity to ask
the RA, the pediatrician, and/or clinic nurse any ques-
tions at any time. For families who provide consent, RAs
























TARGet Kids! Child and Family Questionnaire X
Laboratory measurements: Hemoglobin, serum ferritin, mean
corpuscular volume (MCV), C-reactive protein (CRP)
X X X
IBQ (12-17 months infants)/ECBQ (18-36 months children)/
CBQ (37-72 months children)*
X X X
Physical measurements: height and weight, waist
circumference
X X X
Mullen Scales of Early Learning (MSEL) X X X
4 month follow-up questionnaire X
*IBQ: Infant Behavior Questionnaire; ECBQ: Early Childhood Behavior Questionnaire; CBQ: Children’s Behavior Questionnaire.
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taking the study drug and address any questions parents
may have. Since the study drug is given for four months,
after the four-month follow-up visit no further contact
with the participant is conducted before the 12-month
follow-up visit. Two weeks prior to the 12-month
follow-up visit the RA contacts the participant via phone
and schedules the visit.
Data collection methods
Questionnaire data and physical measurements are col-
lected by the RAs embedded in the practices. The RAs
have been trained to ensure accuracy of data collection and
the questionnaires have been extensively pilot tested. Blood
work is obtained by trained personnel according to the
arrangements established at each of the practice sites. The
RA is responsible for ensuring the blood is delivered to
Mount Sinai Services ((MSS) Toronto, Canada) for labora-
tory testing. MSS provides customized laboratory and
research services to pharmaceutical and biotech compan-
ies, and researchers. Laboratory results are sent electronic-
ally to the data management center, as well as faxed to the
practicing physicians offices. Children eligible for the
randomized trial return to the physician’s office where
developmental testing is completed using the MSEL, ad-
ministered by a trained psychometrist under the supervi-
sion of a registered psychologist. At the four and 12-monthfollow-up visits, the RA is responsible for ensuring that the
questionnaires, and physical and laboratory measures are
completed. The psychometrist completes the MSEL.
Data management
The Applied Health Research Centre (AHRC) of the
Keenan Research Centre, Li Ka Shing Knowledge Institute
of St Michael’s Hospital, University of Toronto, serves as
the data management centre for this trial. AHRC employs
state-of-the-art web-based data management software
RAVE™ (version 5.6.3, Medidata Solutions Inc., New York,
USA), which uses secure encrypted web-based data
capture technology and is the repository for data collected
during this study. It has user configurable workflows, so-
phisticated case report form (CRF) design, complex edit
checking, and customized security parameters. Our RAs
enter data remotely in real time to the central database
from any of the practice sites. RAVE has extensive built-in
reporting capabilities, and data can be exported to
standard formats for data analysis (for example, to SAS
(Statistical Analysis System) software).. Laboratory tests are
directly uploaded to RAVE through a secure web portal.
Trial monitoring
A Data Monitoring Committee was not deemed necessary,
as the experimental intervention (oral iron treatment with
6 mg elemental iron/kg/day given once daily or in two or
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counseling) is the standard of care for children in the same
age group with IDA, and the side effect profile is well
known. In the current study of children with NAID, simi-
lar side effects are expected and are collected.Adverse event reporting
All adverse events will be reported to the Hospital for
Sick Children Research Ethics Board, according to the
Hospital for Sick Children’s adverse event reporting
requirements. All adverse drug reactions to the study
medication will be reported to Health Canada within
15 calendar days or, for death or life-threatening events,
within seven calendar days. In the latter case, a follow-up
report must be filed within eight calendar days. Adverse
reactions will be managed according to the Hospital for
Sick Children’s standard clinical management practices.Statistical analysis
From the screening cohort, the baseline characteristics
of the three groups (NAID, IDA, and IS) will be compared
with descriptive statistics and significance testing. Cat-
egorical variables will be compared with a chi-square
test, and continuous variables will be compared with an
analysis of variance (ANOVA), or non-parametric
equivalent. For participants with NAID randomized to
treatment or placebo groups, no significance testing
will be performed on the baseline characteristics; how-
ever, we will note any imbalances that have arisen by
chance which may be clinically meaningful. All children
with NAID randomized to treatment or placebo will be
analyzed in the group to which they were randomized,
following the intention-to-treat principle. In the primary
analysis, the difference in developmental and hematologic
measures in children with NAID randomized to treatment
versus placebo will be assessed using linear regression,
with the initial baseline measures included as the adjusting
variable (analysis of covariance (ANCOVA) method) [56].
In a secondary analysis, additional covariates of clinical or
statistical significance (including parent education and
family income) will be included in the model. The primary
analysis will be a fixed effects model, ignoring stratification
by clinic site. A secondary analysis will include a confirma-
tory analysis using a mixed effects model, with interven-
tions and MSEL scores as the fixed effect and clinic site as
the random effect. The non-randomized groups (IS and
IDA) will be compared with the NAID groups for differ-
ence in their follow-up developmental and hematological
outcome using ANOVA. Although efforts to ensure
complete data collection and participant follow-up will be
maximized, analytic strategies to handle missing data will
include imputation techniques, if appropriate. If more
than 20% of participants are lost to follow-up, a perprotocol analysis will be carried out in addition to the
intention-to-treat analysis.
Power calculation
Clinically meaningful difference in tests of cognition
The minimal clinically important difference (MCID) for
the primary outcome of interest (child development as
measured by MSEL) has been carefully considered by
our research team [57]. In a landmark longitudinal study
of infants with IDA compared with IS infants followed
from infancy (12 to 23 months) through to 19 years of
age, infants with IDA were found to have an eight to
nine point cognitive disadvantage in infancy. In a subset
of low-income infants the gap widened from 10 points
in infancy to 25 points by 19 years [58-61]. Another piv-
otal study by Walter et al. has suggested that the MCID
for cognitive difference in children may be as low as six
points [62]. Studies in older children have shown that a
15 point cognitive disadvantage at age 11 years conferred
a relative risk of 0.79 of being alive 65 years later, and a
30 point disadvantage reduced this to 0.63 [63]. From
these studies (and a larger body of literature identifying
the association between cognition and education, employ-
ment, and health) 15 points or greater is clearly clinically
meaningful. However, it is important for a trial to have the
power to identify the minimally important difference,
which might be as low as a six to eight point difference.
Sample size calculation for the randomized part of the
OptEC trial (see Figure 1: schematic of study plan) is
based primarily on a presumptive effect estimate of the
ELC score, which we considered as an MCID. ELC being
a summarized indicator of child cognition, we arrived at
a sample size estimate through a sensitivity analysis con-
sidering an array of possible MCIDs (six to eight point
difference) for children’s cognitive development.
From previous research, it is anticipated that the mean
ECL score for children with NAID is 90, and the standard
deviation is ± 15 [22,23,64]. To detect a six to eight point
difference in post-treatment ELC score, with a power of
80% and a significance level of 5%, a total sample size
ranging from 112 to 198 (56 to 99 per group) is required.
We targeted an approximate sample of 150 (75 per group).
Sample size calculation was performed using the t-test
formula [56]. With an estimated prevalence of NAID of
10%, it is anticipated that screening approximately 1,500
children will identify 150 children with NAID to be
randomized over a four-year period [2,52,65]. Expecting
potential drop-outs and withdrawals to be between 0 and
20%, a total of 180 NAID children will be randomized.
For the non-randomized children (IDA and IS), it is an-
ticipated that the mean ELC score for children with
IDA is 85, and the mean developmental score for IS
children is 100, and both have an ELC standard deviation
of ± 15 [22,23,64]. From the screening cohort of 1,500, it
Abdullah et al. Trials  (2015) 16:132 Page 9 of 12is anticipated that 1 to 2% will have IDA (n = 25), and
an equal number of randomly selected children with IS
(n = 25) will be sampled for comparison [52,65]. To
randomly select children with IS, once a child with IDA
is identified, the immediate next child identified with IS
who agrees to participate is enrolled in the trial.
Ethical conduct of the OptEC trial
The OptEC trial was granted ethics approval by The
Hospital for Sick Children Research Ethics Board ((REB)
file number: 1000027782) on 10 May 2012 and approval
is renewed annually by the REB. This study has been
registered as a clinical trial (Clinicaltrials.gov identifier:
NCT01481766). Written informed consent is obtained
from parents of all child participants prior to any data
collection. The OptEC trial has different consent forms
for the three groups of children (NAID, IDA, and IS)
based on their iron status and provision of intervention
(see Additional file 4: 4a, 4b and 4c: Consent forms). All
data collection forms and supporting documents (iron
intake guideline, participant information sheet, and tele-
phone script) were approved by the Hospital for Sick
Children REB. Blood results are provided to the child’s
physician within 24 to 48 hours. Detailed reports of the
MSEL are available in approximately four weeks. Parents
and physicians may perceive the opportunity for a cogni-
tive assessment and laboratory testing to be a direct benefit
of participation in this study. The investigators considered
the inclusion of dietary advice and assessment of outcomes
at four months in all randomized children to be consistent
with good clinical practice. If at four months children
in either the intervention or control group have persistent
NAID or have progressed to IDA, they are treated and
monitored accordingly by their primary physician.
Discussion
An internal pilot study to guide the protocol of the OptEC
trial
The estimates used for the calculation of the sample size
for the OptEC trial were derived from previous trials
which differed from the trial currently being designed;
for example, different patient population, small numbers
of centers, and different treatment duration [66,67]. Appli-
cation of prior estimates for power calculation of the
current trial may lead to an unnecessarily large trial, or
the trial may not be large enough to have sufficient power
for detection of a clinically relevant treatment effect
[66,68]. Therefore, an internal pilot study was initiated.
Internal pilot study
An internal pilot is incorporated into the main study de-
sign of a randomized controlled trial to obtain important
parameter estimates. It forms an integral part of the trial
itself and is not a separate study. The protocol of therandomized controlled trial designates the first phase of
the trial as a ‘pilot’ phase. These estimated parameters
are then used to recalculate the sample size or improve
the design and conduct of the clinical trial [66,67]. At
the end of the trial, data analyses incorporates those col-
lected during the internal pilot, as well as those collected
subsequently. Building an internal pilot study into a clin-
ical trial has very small adverse effect on the significance
level [66,69]. Other possible uses of internal pilot data
include checking the assumptions regarding adherence
of the participants to the study intervention [66,70].
Non-adherence may decrease the probability of detect-
ing treatment differences and affect the interpretation of
observed differences. Poor adherence can also jeopardize
the outcome of clinical trials by reducing their power.
Using data from an internal pilot can provide the antici-
pated adherence level of participants of a larger clinical
trial and can be used to implement strategies to enhance
compliance [71,72].
Aim of the OptEC trial internal pilot study
The objectives of the internal pilot study are: to obtain a
reliable estimate of the standard deviation (S2) of the
primary outcome of the OptEC trial; to obtain the cor-
relation between the baseline and follow-up measure-
ment of the primary outcome; to recalculate the sample
size of the OptEC trial using the estimates generated
from the internal pilot; and to assess the adherence rate
and causes of non-compliance in children enrolled in
the pilot study.
Sample size for the internal pilot study
Several authors have considered approaches to pre-
selecting the sample size for internal pilot studies. One
approach has shown through simulation that to receive
a reliable estimate of the true population parameter, the
minimum size for an internal pilot should be at least 10
subjects per treatment group for a two-group randomized
study [66]. The sample size for the OptEC trial is approxi-
mately 150 (75 per group) NAID subjects to be random-
ized over a period of four years. Thus, we planned an
internal pilot using the first 30 NAID (15 per group)
subjects randomized to the two treatments groups.
Methods
When the trial has assessed the endpoints for the 30
participants in the internal pilot, we will calculate the
observed standard deviation within each group and pool
them to obtain an estimated standard deviation (S2). If
S2 ≤ 15, the trial will continue as planned, so that the
total sample size remains between 112 and 198. How-
ever, if S2 > 15, we will recalculate the sample size using
the new estimate of the standard deviation (S2) [66]. Re-
calculation of the sample will be performed using the
Abdullah et al. Trials  (2015) 16:132 Page 10 of 12ANCOVA method. This method uses the correlation be-
tween the baseline and follow-up measurement of the
primary outcome in sample size calculation [56].
For assessment of adherence, an adherence rate will be
calculated using data from the internal pilot study [72,73].
The four-month follow-up form of the OptEC trial col-
lects data on causes of non-adherence, adverse effects, and
an approximate per week rate of missed doses of the study
drug. This self-reported measure of missed doses will be
used to assess the rate of compliance using a method pro-
posed by Klerk et al. [74]. In this method, summaries such
as the total number of days in which no doses were taken,
the length of the monitored interval, and the overall per-
centage of prescribed doses taken is used to calculate a
rate of adherence [73,74]. Adherence rate will be described
by placing participants into broad bands, with the percent-
age of patients in each band. The causes of non-adherence
will be identified and summarized as percentage.Knowledge translation
Findings from this research will be disseminated directly to
the physician participants and to their patients. An annual
meeting of all the TARGet Kids! Practice staff (physicians,
nurses, and office staff ), research team (investigators,
research assistants, and students), and policy leaders
(representatives from Section of Community Pediatrics,
Department of Family and Community Medicine, and
parent representatives) will occur. Parents of participants
will receive the summary of their child’s developmental
assessment, anthropometric measures, and laboratory
measures, leading to a direct benefit for individual par-
ticipants. Further downstream dissemination to pri-
mary care physicians will occur through formal and
informal venues at local levels, such as educational
rounds (for example City Wide Pediatric Rounds and
SickKids Annual Pediatric Update) and held by local
physician groups. End of grant knowledge will be shared
with the academic community through publication in
relevant journals and presentations at national and
international conferences (Annual Meetings of the
Pediatric Academic Societies, and the Canadian Paediatric
Society), and locally through hospital rounds and presen-
tations, and through our TARGet Kids! website [75].
Messages will be relevant to professionals working in
the fields of pediatrics, family medicine, developmental
pediatrics, nutrition, nursing, dietetics, and public
health. We will also share our findings with colleagues at
the Canadian Paediatric Society and the American
Academy of Pediatrics. The principal applicant is a
member of the Canadian Task Force for Preventive
Health Care and will participate in the upcoming guideline
development for developmental screening and screening
for IDA. Opportunities for coverage in lay publicationsand media will be sought using an experienced knowledge
broker at SickKids Department of Public Relations.
Trial status
The trial has been recruiting since July 2012. The end of
recruitment is estimated to be June 2016.
Additional files
Additional file 1: The SPIRIT checklist.
Additional file 2: Iron intake guideline.
Additional file 3: 4 month follow-up form.
Additional file 4: 4a, 4b and 4c: Consent forms.
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